BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax (VEN) is a potent oral inhibitor of the antiapoptotic molecule BCL2, used to treat adults with chronic lymphocytic leukaemia (CLL), in association with obinutuzumab in patients who have not previously been treated or with rituximab in patients who have received at least one previous treatment.